CSIMarket Company Name, Ticker, Customers, else..


Reata Pharmaceuticals Inc   (NASDAQ: RETA)
Other Ticker:  
 

Reata Pharmaceuticals Inc

RETA's Fundamental analysis



Looking into Reata Pharmaceuticals Inc growth rates, revenue grew by 2885.04 % in II. Quarter 2023 from the same quarter a year ago. Ranking at No. 37

Major Pharmaceutical Preparations industry recorded deterioration of revenues by -8.1 %

Reata Pharmaceuticals Inc realized net income compared to net loss a year ago in II. Quarter 2023

• More on RETA's Growth


Reata Pharmaceuticals Inc
realized a net loss in trailing twelve months.

Reata Pharmaceuticals Inc realized cash reduction of $ -2.37 per share in trailing twelve-month period.
Company
-
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 304.68.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.46.


• More on RETA's Valuation
 
 Total Debt (Millions $) 73
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 67,089
 Net Income/Employee (TTM) $ -250,351
 Receivable Turnover (TTM) 4.14
 Tangible Book Value (Per Share $) 2.10

Reata Pharmaceuticals Inc
realized net loss in trailing twelve months.

Reata Pharmaceuticals Inc realized cash outflow of $ -2.37per share in trailing twelve-month period.
Company
-
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 304.68.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.46.

Reata Pharmaceuticals Inc Price to Book Ratio is at 81.96 lower than Industry Avg. of 83.08. and higher than S&P 500 Avg. of 0.02

• More on RETA's Valuation

•  Market Capitalization (Millions $) 7,154
•  Shares Outstanding (Millions) 42
•  Employees 350
•  Revenues (TTM) (Millions $) 23
•  Net Income (TTM) (Millions $) -88
•  Cash Flow (TTM) (Millions $) -98
•  Capital Exp. (TTM) (Millions $) -1
•  Total Debt (Millions $) 73
•  Dividend TTM ($) 0 $
•  Dividend Yield TTM (%) -
•  Revenue/Employee (TTM) $ 67,089
•  Net Income/Employee(TTM) $ -250,351
•  Receivable Turnover Ratio (TTM) 4.14
•  Tangible Book Value (Per Share $) 2.10

•  Market Capitalization (Millions $) 7,154
•  Shares Outstanding (Millions) 42
•  Employees 350
•  Revenues (TTM) (Millions $) 23
•  Net Income (TTM) (Millions $) -88
•  Cash Flow (TTM) (Millions $) -98
•  Capital Exp. (TTM) (Millions $) -1





  Ratio
•   Capital Ratio (MRQ) 3.21
•  Total Debt to Equity (MRQ) 0.84
•  Tangible Leverage Ratio (MRQ) 2.27
•  Asset Turnover Ratio (TTM) 0.05
•  Inventory Turnover Ratio (TTM) -





Reata Pharmaceuticals Inc net profit margin of 848.49 % is currently ranking no. 5 in Major Pharmaceutical Preparations industry, ranking no. 6 in Healthcare sector and number 26 in S&P 500.

• More on RETA's Key Ratios





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com